Bob is Co-Founder of Accent Therapeutics and served as their President and Chief Scientific Officer from 2017 through 2024. He was formerly President of Research and CSO of Epizyme and before that, VP of Cancer Biology at GlaxoSmithKline. He has contributed to drug discovery and development efforts leading to 20 investigational new drugs entering human clinical trials, five of which are today FDA-approved medicines. Bob has authored more than 200 scientific publications, 6 books, and holds 14 issued U.S. patents. He was elected a Fellow of the American Association for the Advancement of Science (AAAS) and of the Royal Society of Chemistry. Bob received his doctorate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology.